VistaGen Therapeutics
VTGN
101 hedge funds and large institutions have $387M invested in VistaGen Therapeutics in 2021 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 23 increasing their positions, 22 reducing their positions, and 19 closing their positions.
142% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 19
71% more capital invested
Capital invested by funds: $227M → $387M (+$160M)
36% more funds holding
Funds holding: 74 → 101 (+27)
5% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.31% less ownership
Funds ownership: 2.46% → 2.15% (-0.31%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$22.2M |
| 2 |
O
OrbiMed
New York
|
+$14.5M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$7.56M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$6.02M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$5.29M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$4.86M |
| 4 |
Millennium Management
New York
|
-$3.01M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$2.71M |
VTGN Hedge Fund Activity: Q2 2021 in Review
101 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2021, worth a combined $387M — up 71% from $227M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new VTGN positions and 19 closed out — a net gain of 27 holders — while 23 added to existing stakes and 22 trimmed.
The largest buyer was BlackRock, adding an estimated $22.2M. The largest seller was Marshall Wace North America, exiting entirely with an estimated $6.02M sold.
- 101 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2021, up from 74 in Q1 2021.
- Funds reported $387M of VistaGen Therapeutics stock for Q2 2021, up 71% quarter-over-quarter.
- 46 funds opened new VistaGen Therapeutics positions in Q2 2021 and 19 closed out, a net change of +27 holders.
- The largest VistaGen Therapeutics buyer in Q2 2021 was BlackRock, an estimated $22.2M added.
- The largest VistaGen Therapeutics seller in Q2 2021 was Marshall Wace North America, an estimated $6.02M sold.
Based on aggregated 13F filings for Q2 2021.